The impact factor of Drug Designing journal is a measure reflecting the average number of citations to recent articles published in the journal. It is frequently used as a proxy for the relative importance of a journal within its fields, with journals with higher impact factors estimated to be more important than those with lower ones. The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information. Drug Designing Impact factors are calculated yearly starting from 2011 for those journals that are indexed in the Journal Citation Reports. A journal can adopt editorial policies to increase its impact factor. For example, journals may publish a larger percentage of review articles which generally are cited more than the research reports. articles can raise the impact factor of the journal and review journals will therefore often have the highest impact factors in their respective fields. Some journal editors set their submissions policy to "by invitation only" to invite exclusively senior scientists to publish "citable" papers to increase the journal impact factor. Journals may also attempt to limit the number of "citable items" i.e., the denominator of the impact factor equation either by declining to publish articles that are unlikely to be cited or by altering articles in hopes that Thomson Scientific Regulator will not deem it a "citable item". As a result of negotiations over whether items are "citable", impact factor variations of more than 300% have been observed. Interestingly, items considered to be not citable and thus are not incorporated in impact factor calculations can, if cited, still enter into the numerator part of the equation despite the ease with which such citations could be excluded. This effect is hard to evaluate, for the distinction between editorial comment and short original articles is not always obvious. For example, letters to the editor may refer to either class.
Chemotherapy is the use of medicines or drugs to treat cancer. The thought of having chemotherapy frightens many people. But knowing what chemotherapy is, how it works, and what to expect can often help calm your fears. It can also give you a better sense of control over your cancer treatment. A major obstacle to control cancer growth and metastasis in patients is the widespread inappropriate use of anticancer drugs. As increasing numbers and types of anticancer drugs has been developed, clinicians become more and more likely to misuse them in their practice. We have known that cancers are diff erent etiological diseases with the same pathologic characteristics of unlimited growths. With this type of heterogenous characters, it means responses to same anticancer drugs can be various from patient to patient even though they all develop from same organs of humans, or even represent with same histological tissues or phenotype. Owing to all these reasons, individualized cancer chemotherapy will be a future trend to improve the anticancer drug applications in clinics. In this article, we will document, review, discuss and highlight this issue.
Last date updated on July, 2014